



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



Chemokine-Like Receptor 1 Blocking Peptide

Item No. 10326

Overview and Properties

Contents:	This vial contains 200 µg of peptide.
Synonyms:	CMKLR1, DEZ, GPCR ChemR23, Resolvin E1 Receptor
Form:	Liquid
Storage:	-20°C (as supplied)
Storage Buffer:	TBS, pH 7.4, containing 0.1% BSA and 0.02% sodium azide
Stability:	As supplied, 1 year from the QC date provided on the Certificate of Analysis, when stored properly

Procedures

This vial contains 200 µg of peptide in TBS, pH 7.4, containing 0.1% BSA and 0.02% sodium azide. This blocking peptide can be used in conjunction with Cayman's Chemokine-Like Receptor 1 Polyclonal Antibody (Item No. 10325) to block protein-antibody complex formation during immunochemical analysis of Chemokine-Like Receptor 1. We recommend an antibody and peptide incubation of 30 minutes at 25°C prior to application to the slide or membrane to preadsorb the IgG from the target protein.

To block antibody/protein complex formation, the following procedure is recommended:

1. Mix the Chemokine-Like Receptor 1 Polyclonal Antibody (Item No. 10325) and blocking peptide together in a 1:1 (v/v) ratio in a microfuge tube. For example, mix 20 µl of antibody and 20 µl of peptide.*
2. Incubate for one hour at room temperature with occasional mixing prior to further dilution and application of the mixture to the immunoblot.
3. Dilute the mixture to the final working antibody concentration and apply to the slide or membrane as usual.

*This is a recommended mixture. The minimum amount of peptide needed for complete blocking has not been precisely determined and may vary depending on the sample being analyzed. The amount of peptide required may need to be increased if sufficient blocking does not occur.

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/06/2017

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM

PRODUCT INFORMATION



Description

Chemokine-Like Receptor 1 (CMKLR1) is a G protein-coupled receptor relevant to the cellular chemotaxis of dendritic cells and macrophages.¹ This receptor is also expressed in brain, liver, lung, and kidney tissues.^{1,2} Chemerin (TIG2) has been identified as the natural ligand for this receptor.³ Resolvin E1 has also been identified as a ligand for CMKLR1; acting to dampen cellular responses to inflammation.^{1,4,5} Chemerin is an 18 kDa protein that plays a role in immunity, inflammation, chemotaxis, and has been identified as an adipokine.^{2,6,7} Human CMKLR1 shares 80% sequence homology with its murine ortholog.³ The human receptor exists in two isoforms, differing only by two amino acids due to a premature stop codon. Isoform one has 363 amino acids and an expected molecular weight of 42.3 kDa. Cayman's CMKLR1 polyclonal antibody recognizes the C-terminal region of the protein and cell permeabilization is recommended prior to whole cell staining.

References

1. Arita, M., Bianchini, F., Aliberti, J., *et al.* Stereochemical assignment, anti-inflammatory properties, and receptor for the ω -3 lipid mediator resolvin E1. *J. Exp. Med.* **201(5)**, 713-722 (2005).
2. Takahashi, M., Takahashi, Y., Takahashi, K., *et al.* Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. *FEBS Lett.* **582**, 573-578 (2008).
3. Wittamer, V., Grégoire, F., Robberecht, P., *et al.* The C-terminal nonapeptide of mature chemerin activates the chemerin receptor with low nanomolar potency. *J. Biol. Chem.* **279(11)**, 9956-9962 (2004).
4. Arita, M., Ohira, T., Sun, Y.-P., *et al.* Resolvin E1 selectively interacts with leukotriene B₄ receptor BLT₁ and ChemR23 to regulate inflammation. *J. Immunol.* **178**, 3912-3917 (2007).
5. Cash, J.L., Hart, R., Russ, A., *et al.* Synthetic chemerin-derived peptides suppress inflammation through ChemR23. *JEM* **205(4)**, 767-775 (2008).
6. Roh, S.-G., Song, S.-H., Choi, K.-C., *et al.* Chemerin-a new adipokine that modulates adipogenesis via its own receptor. *Biochem. Biophys. Res. Commun.* **362**, 1013-1018 (2007).
7. Campbell, E.L., Louis, N.A., Tomassetti, S.E., *et al.* Resolvin E1 promotes mucosal surface clearance of neutrophils: A new paradigm for inflammatory resolution. *FASEB J.* **21**, 3162-3170 (2007).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM